Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
(4) - EconoTimes)
SAN DIEGO, April 25, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported grants under its Amended and Restated 2017 Inducement Equity Incentive Plan to two new employees who joined Vital Therapies.
The grants made April 24, 2018 are awards of nonstatutory stock options to purchase up to a total of 32,526 shares of Vital Therapies common stock. The options have an exercise price of $5.50, the closing price of Vital Therapies’ common stock on the grant date. The option grants will vest over four years with 1/48th of the total shares vesting monthly, subject to continued service. Each stock option has a ten-year term and is subject to the terms and conditions of the Amended and Restated 2017 Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The grants were approved by the Vital Therapies Board of Directors on April 24, 2018. In accordance with NASDAQ Listing Rule 5635(c)(4), the grants were made as an inducement material to entering into an employment relationship with Vital Therapies.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
